Quince Therapeutics publishes eDSP study data in pulmonary, IBD disorders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. CVI

Go back to Quince Therapeutics publishes eDSP study data in pulmonary, IBD disorders

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

December 10, 2025 4:05 PM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patients own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers in Drug Delivery.

Dirk Thye, M.D., Quinces Chief Executive Officer and Chief Medical Officer, said, This new... More